RIBOZYME PHARMACEUTICALS
Ribozyme Pharmaceuticals is a biotechnology company. It develops therapeutics based on RNA interference (RNAi) technology. The company provides research, preclinical, and clinical development services with product candidates in various areas including age-related macular degeneration (AMD), chronic hepatitis, dermatology, asthma, Huntington’s disease (HD), oncology, and diabetes. It offers Sirna-027, which completed phase I clinical trial and is used for the treatment of AMD; Sirna-034, ... which is under preclinical stage and is used for the treatment of hepatitis C virus; and various drugs under preclinical stage of development for asthma, HD, chronic hepatitis, diabetes, and dermatology. The company has strategic alliances with Allergan, Inc., Eli Lilly and Company, Targeted Genetics, Protiva, Archemix Corporation, and GlaxoSmithKline. Ribozyme Pharmaceuticals was founded in 1992 and is headquartered in San Francisco, California. As of March 5, 2014, it operates as a subsidiary of Alnylam Pharmaceuticals.
RIBOZYME PHARMACEUTICALS
Industry:
Biotechnology Health Care
Founded:
1992-01-01
Address:
Boulder, Colorado, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
12 M USD
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Current Employees Featured
Investors List
Morgenthaler Ventures
Morgenthaler Ventures investment in Series B - Ribozyme Pharmaceuticals
More informations about "Ribozyme Pharmaceuticals"
Ribozyme Pharmaceuticals - Crunchbase
Ribozyme Pharmaceuticals, Arrowhead Pharmaceuticals, Celator Pharmaceuticals, and Virscio are all part of the biotechnology sector. Ribozyme and Arrowhead focus on developing …See details»
Ribozyme Pharmaceuticals - Funding, Financials, Valuation
Ribozyme Pharmaceuticals is a biotechnology company that develops therapeutics based on RNA interference (RNAi) technology. New. Resources. Advanced Search. ... How much …See details»
RIBOZYME PHARMACEUTICALS INC (Form: S-8, Filing Date: …
Incorporation or Organization) Number) 2950 Wilderness Place, Boulder, Colorado 80301 ... Marvin Tancer COPIES TO: Ribozyme Pharmaceuticals, Inc. Karen L. Witt, Esq. 2950 …See details»
RIBOZYME PHARMACEUTICALS INC (Form: S-8, Filing Date: …
RIBOZYME PHARMACEUTICALS, INC.----- (Exact Name of Registrant as Specified in its Charter) ... Jurisdiction of Identification Incorporation or Organization) Number) 2950 …See details»
INDUSTRY TRENDS Ribozyme therapeutics - Nature
Which was founded in 1993; and Ribozyme Pharmaceuticals (Boulder, CO), which was founded in 1992 and went public in 1996, raising $28.4 million. Ribozymes are emerging as a potentially …See details»
RIBOZYME PHARMACEUTICALS, INC | TREA
Jan 24, 2025 Short interfering nucleic acid (siNA) compositions. Patent number 11,530,407; Issue date Dec 20, 2022; SIRNA Therapeutics, Inc. Brian Allen CarrSee details»
Ribozyme Pharmaceuticals (Ribozyme Pharmaceuticals) - 药物管 …
了解Ribozyme Pharmaceuticals (Ribozyme Pharmaceuticals)公司的药物管线，治疗领域，技术平台，以及它的1篇新闻和13篇文献。 ... 2017, he has served on the board of the Digital …See details»
Ribozyme raises $9.5 million - Pharmaceutical industry news | The ...
Nov 30, 2001 Ribozyme Pharmaceuticals of the USA says that it has received grossproceeds of $9.5 million from an offering to selected institutional investors of almost 2.3 million newly …See details»
RZNOMICS Inc. received FDA approval to initiate clinical …
SEONGNAM, South Korea, Oct. 25, 2022 /PRNewswire/ -- Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, …See details»
Ribozyme - Wikipedia
The next ribozyme discovered was the "tC19Z" ribozyme, which can add up to 95 nucleotides with a fidelity of 0.0083 mutations/nucleotide. [28] Next, the "tC9Y" ribozyme was discovered by researchers and was further able to synthesize …See details»
Simplification for success: Rewiring the biopharma operating …
1 day ago Thirty-seven of them expect their organization to pursue a simplification effort over the next 12 months. Thirty-two respondents say they believe they need a significantly different …See details»
Ribozyme Pharmaceuticals - Updates, News, Events, Signals
Ribozyme Pharmaceuticals is a biotechnology company that develops therapeutics based on RNA interference (RNAi) technology. ... Log In. Log In. Experience the new Crunchbase, …See details»
Ribozyme Pharmaceuticals Going Into Clinical Trials with Herzyme ...
Jun 6, 2000 The first ribozyme in this series, Amberzyme, was described earlier this year (reference 1). These new nuclease-resistant ribozyme motifs add to RPI's ribozyme arsenal by …See details»
Ribozymes as Therapeutic Agents against Infectious Diseases
Sep 29, 2022 Ribozymes, also known as RNA enzymes, are catalytic RNA molecules capable of cleaving specific RNA sequences, leading to decreased expression of targeted genes. Recent …See details»
Fibrosis: cross-organ biology and pathways to development of …
4 days ago Fibrosis is a pathophysiological mechanism involved in chronic and progressive diseases that results in excessive tissue scarring. Diseases associated with fibrosis include …See details»
Ribozyme - an overview | ScienceDirect Topics
A ribozyme antiviral for hepatitis C has been proposed, 58 and ribozyme antivirals for HIV are being developed. 59 The utilization of genetically manipulated cells capable of producing …See details»
CHAPTER 18: Therapeutic Potential of Ribozymes - Royal Society …
Feb 8, 2019 Furthermore, ribozymes have been engineered to allow site-directed RNA sequence alterations, enabling the correction of genetic misinformation at the RNA level. This …See details»
The Therapeutic Potential of Ribozymes | Blood - American Society …
Jan 15, 1998 The ribozyme recognizes sequences either side of a substrate NUH site by means of the flanking arms. The catalytic core then cleaves the RNA 3′ of the NUH triplet. The hairpin …See details»
Ribozymes - Latest research and news - Nature
Feb 3, 2025 A ribozyme is a ribonucleic acid (RNA) molecule with the ability to catalyze a biochemical reaction a function more commonly carried out by proteins. It is generally believed …See details»
Ribocentre: a database of ribozymes - PubMed
Jan 6, 2023 We have therefore created Ribocentre, a database that collects together sequence, structure and mechanistic data on 21 ribozyme families. This includes available information on …See details»